Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD7762 + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD7762||AZD-7762||CHK Inhibitor (Pan) 2||AZD7762 is an ATP-competitive CHK1/CHK2 inhibitor, which abrogates DNA damage-induced cell cycle checkpoints, and demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776, PMID: 32335582, PMID: 31372095).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||no benefit||AZD7762 + Gemcitabine||Phase I||Actionable||In a Phase I trial, the CHEK2 inhibitor, AZD7762, in combination with Gemzar (gemcitabine), demonstrated some efficacy in two solid tumors patients, however the cardiac toxicity was unfavorable (PMID: 24448638).||24448638|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|